Showing 4061-4070 of 5623 results for "".
- Glaukos Announces Positive Topline Outcomes in Two Phase 3 Pivotal Trials of iDose TRhttps://modernod.com/news/glaukos-announces-positive-topline-outcomes-for-both-phase-3-pivotal-trials-of-idose-tr/2481092/Glaukos announced positive topline data for both phase 3 pivotal trials of iDose TR that successfully achieved its prespecified primary efficacy endpoints through 3 months in both phase 3 trials and demonstrated excellent tolerability and a favorable safety profile through 1
- Bausch + Lomb Sponsored Visionary Report Spotlights Nation's 'Blind Spots' on AMDhttps://modernod.com/news/bausch-lomb-sponsored-visionary-report-spotlights-nations-blind-spots-on-amd/2481091/Bausch + Lomb released a report of survey results from the company’s first Visionary Report, which was designed to identify new key insights into the value Americans place on their eyesight, as well as the ‘blind spots’ that may exist in the understanding and aware
- Sight Sciences Announces Completion of Enrollment in SAHARA, a Randomized Clinical Trial of the TearCare System vs Restasishttps://modernod.com/news/sight-sciences-announces-completion-of-enrollment-in-sahara-a-randomized-clinical-trial-of-the-tearcare-system-vs-restasis/2481086/Sight Sciences announced the completion of enrollment in the SAHARA trial, a study designed to evaluate whether an interventional dry eye procedure with the TearCare System is superior in alleviating the signs and symptoms of dry eye disease compared to 6-months of twice daily Restasis&
- Ciliatech Presents New Concept in Glaucoma Implants, First to Bypass Opening Anterior Eye Chamberhttps://modernod.com/news/ciliatech-presents-new-concept-in-glaucoma-implants-first-to-bypass-opening-anterior-eye-chamber/2481085/Ciliatech, which is developing a new class of implant to treat glaucoma durably named
- Pixium Vision Announces Implantation of First Patient in Italy in Prima System European Pivotal Trial PRIMAverahttps://modernod.com/news/pixium-vision-announces-implantation-of-first-patient-in-italy-in-prima-system-european-pivotal-trial-primavera/2481084/Pixium Vision announced the successful first implantation of a patient in Italy in the PRIMAvera pivotal trial in atrophic dry age-related macular degeneration (dry AMD). This follows the approval of the PRIMAvera study by the Italian Ministry of Health and the opening of the first clinical
- Johnson & Johnson Vision Launches Acuvue Oasys Max 1-Dayhttps://modernod.com/news/johnson-johnson-vision-launches-acuvue-oasys-max-1-day/2481083/Johnson & Johnson Vision Care announced the launch of its newest innovation, Acuvue Oasys Max 1-Day contact lenses and Acuvue Oasys Max 1-Day Multifocal contact lenses for presbyopia. The lenses are designed with a combination of new technologies to help meet the needs of digit
- Rayner to Announce Launch of RayPRO+ Digital Health Platform at the ESCRShttps://modernod.com/news/rayner-to-announce-launch-of-raypro-digital-health-platform-at-the-escrs/2481082/Rayner announced the global launch of RayPRO+ at the upcoming ESCRS 2022 congress in Milan. RayPRO is Rayner’s proprietary mobile app and web-based digital platform that proactively collects a blend of patient reported outcomes (PROs) over 3 years. RayPRO+ has the added ability to
- Trukera Medical Launches ScoutPro Osmolarity Systemhttps://modernod.com/news/trukera-medical-launches-new-scoutpro-osmolarity-system/2481081/Trukera Medical unveiled the first product under the new company name, the ScoutPro Osmolarity System. Designed to help advance corneal health decisions for busy eye care practices, ScoutPro is the first and only portable osmometer in the United States. The launch comes a wee
- Cellusion and Celregen Enter into License Agreement of CLS001 for a Corneal Endothelial Cell Regenerative Therapy in the Greater Chinahttps://modernod.com/news/cellusion-and-celregen-enter-into-license-agreement-of-cls001-for-a-corneal-endothelial-cell-regenerative-therapy-in-the-greater-china/2481079/Cellusion, a Japanese regenerative medicine startup, and Hangzhou Celregen Therapeutics, a member of Shanghai Fosun Pharmaceutical, announced an exclusive license agreement in the Greater China region for Celregen to develop, manufacture and commercialize CLS001. Under the agr
- Aflibercept 8 mg Meets Primary Endpoints in Two Global Pivotal Trials for DME and Wet AMD for 12- and 16-Week Dosinghttps://modernod.com/news/aflibercept-8-mg-meets-primary-endpoints-in-two-global-pivotal-trials-for-dme-and-wet-amd-for-12-and-16-week-dosing/2481071/Regeneron Pharmaceuticals announced that the primary endpoints were met in two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens in patients with diabetic macular edema (DME) and wet age-related macular degeneration (AMD). The PHOTON trial in DME and the PUL